About 75% of breast cancers are ERα-positive [41]; furthermore, cumulative data from clinical trials [42,43,44] and retrospective data analyses [42] suggest that ERα-positive breast cancer is more tolerant to some chemotherapeutic agents. This evidence concerns the gene ESR1 and breast carcinoma.